U.S., Dec. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07264985) titled 'Gut Microbiota and Diarrhea in Breast Cancer Patients Receiving Pyrotinib' on Nov. 24.
Brief Summary: Background:
Pyrotinib is an effective targeted drug for HER2-positive breast cancer, but it very frequently causes diarrhea, which can be severe enough to disrupt treatment and reduce patients' quality of life. The reason why some patients develop diarrhea while others do not is not well understood. Recent research suggests that the community of bacteria in the gut (gut microbiota) may play a key role in this side effect.
What is the purpose of this study? This is an observational study (Phase 1) that aims to understand the relatio...